find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
60
Clinical Trials
Lymphoma
Phase II
Accepting Patients
nct/study# NCT04002401 / KT-US-471-0114
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Axicabtagene Ciloleucel In Combination With Either Rituximab Or Lenalidomide In Subjects With Refractory Large B-Cell Lymphoma (ZUMA-14)
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NA / CORE-CLL-2018-0338
Chronic Lymphocytic Leukemia (Cll) Collaborative Study Of Real-World Evidence (Core)
Learn More
Lymphoma
Phase III
Accepting Patients
nct/study# NCT04285567 / CO41685
A Prospective, Open-Label, Multicenter Randomized Phase III Study To Compare The Efficacy And Safety Of A Combined Regimen Of Venetoclax And Obinutuzumab Versus Fludarabine, Cyclophosphamide, And Rituximab (FCR)/Bendamustine And Rituximab (BR) In FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) Or TP53 Mutation
Learn More
Lymphoma
Phase II
Accepting Patients
nct/study# NCT04728893 / MK-1026-003
A Phase 2 Study To Evaluate The Efficacy And Safety Of MK-1026 In Participants With Hematologic Malignancies
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NA / 2021-0129
“Retrospective Review Of Outcomes And Prognostic Factors Of Patients With COVID-19 Infection And Lymphoid Malignancy”
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NCT03888105 / R1979-ONC-1625-US
An Open-Label Study To Assess The Anti-Tumor Activity And Safety Of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Antibody, In Patients With Relapsed Or Refractory Follicular Lymphoma
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.